Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Topoisomerase inhibitors ovarian cancer

Drugs that can be used to control tumour cell proliferation inhibit a variety of enzymes, including thymidylate synthase and topoisomerase (Chapter 20). The enzyme aromatase converts a ring in a steroid to an aromatic ring. It converts, for example, adrenal steroid hormones into female sex hormones, which bind to oestrogenic receptors in the ovary or breast and increase the risk of ovarian or breast cancer. Aromatase inhibitors are used to treat patients with breast or ovarian cancers that are sensitive to oestrogen. Unfortunately, none of the inhibitors is specific for enzymes in tumour cells and they can therefore have severe side-effects (Chapter 21). [Pg.60]

They cause substantial DNA damage in tumor cells, preventing tumor growth. Topotecan has been evaluated in metastatic ovarian cancer. Irinotecan is a prodrug that is metabolized to a topoisomerase I inhibitor it has been used in the treatment of colon and... [Pg.453]

Cositecan (Karenitecin , BNP 1350) 54 (BioNumerik and ASKA Pharmaceutical) is currently being evaluated in a Phase III trial for the treatment of patients with advanced ovarian cancer who have become resistant to platinum and taxane drugs.110 Cositecan 54,111 114 which is also being evaluated against solid tumours in a Phase I trial, is an orally bioavailable, lipophilic 7-[2-(tri-methylsilyl)ethyl] derivative of camptothecin 55 which is less sensitive to both common and camptothecin-specific resistance mechanisms. Camptothecin 55 was first isolated in 1958 from Camptotheca acuminata (Nyssaceae) and its structure was reported in 1966.115 117 Camptothecin 55 was later shown to be a topoisomerase I inhibitor two camptothecin derivatives, topotecan and iri-notecan, are approved for chemotherapy use. [Pg.333]

Topoisomerase inhibitor Lung, ovarian cancer OSI Pharm II... [Pg.484]

Calvert, A. H., Grimshaw, R., Poole, C., Dark, G., Swnerton, K., Gore, M., et al. (2002), Randomized phase II trial of two intravenous schedules of the liposomal topoisomerase I inhibitor, NX211, in women with relapsed epithelial ovarian cancer (OVCA) An NCIC CTG study, Proc. Am. Soc. Clin. Oncol., 21, 208a. [Pg.533]

Topoisomerase I inhibitors Irinotecan (CPT-11 Camptosar) Colon cancer NSCLC SCLC cervical and ovarian cancers gastric cancer pancreatic cancer... [Pg.2303]

Doxorubicin is a nonspecific inhibitor of topoiso-merase I and II. Topotecan and irinotecan selectively inhibit topoisomerase I, an enzyme required for DNA replication. These agents have clinical efficacy in relapsed ovarian and colorectal cancer, respectively. Dose limiting toxicity is bone marrow depression and, in the case of irinotecan, delayed diarrhoea. Administration of irinotecan may be complicated by an acute cholinergic reaction, reversible by administering atropine s.c. [Pg.608]


See other pages where Topoisomerase inhibitors ovarian cancer is mentioned: [Pg.1468]    [Pg.861]    [Pg.277]    [Pg.171]    [Pg.885]    [Pg.223]    [Pg.35]    [Pg.35]    [Pg.179]    [Pg.554]    [Pg.311]    [Pg.162]   
See also in sourсe #XX -- [ Pg.707 ]




SEARCH



Ovarian cancer

Topoisomerase

Topoisomerase inhibitors

Topoisomerases

© 2024 chempedia.info